Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings
NEW YORK, Jan 14, 2026, 11:47 EST — Regular session Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID. This move is crucial as investors demand evidence that Pfizer can develop fresh growth drivers ahead of a tough run of patent expirations. Obesity remains one of the few treatment areas attracting significant investment and rapid uptake, though competition is already fierce. At this week’s J.P. Morgan Healthcare Conference, Bourla laid out expectations for the year ahead as traders focus on whether pipeline